The above abstract from Journal of Crohn’s and Colitis ‘An interim analysis of real-world safety data from an ongoing, non-interventional, observational study of patients with inflammatory bowel disease treated with CT-P13, an infliximab biosimilar, in the context of usual care with reference infliximab’ by B Bokemeyer, T Hlavaty, M Allez, P Selema, S Moosavi, M J Cadatal, H Fowler, R Cheung, M Lukas and J P Gisbert, published online on 15 January 2019 by Oxford University Press has been retracted by agreement between the authors, the journal Editor-in-Chief, Laurence Egan, the European Crohn’s and Colitis Organisation and Oxford University Press. The retraction has been agreed because of data discrepancies. A total of 274 patients were misallocated to the treatment group ‘CT-P13’ for the data analysis. These patients were previously treated with Remicade before study enrollment, and should have been allocated to the ‘Switched from Remicade’ group.

中文翻译：

---

撤回：一项对正在进行的，非介入性观察性研究的真实世界安全性数据的中期分析，该研究是在常规护理下使用英夫利昔单抗的CT-P13（英夫利昔单抗生物仿制药）治疗的炎症性肠病患者

上面的克罗恩与结肠炎杂志摘要B Bokemeyer所做的“一项正在进行的，非干预性观察性研究的现实世界安全性数据的中期分析，该研究是在常规护理下以英夫利昔单抗为基础，对使用英夫利昔单抗生物仿制药CT-P13治疗的炎症性肠病患者进行的，牛津大学出版社于2019年1月15日在网上发布的T Hlavaty，M Allez，P Selema，S Moosavi，MJ Cadatal，H Fowler，R Cheung，M Lukas和JP Gisbert于2019年1月15日在网上发表，经作者之间的协议已撤回，首席，劳伦斯·伊根（Laurence Egan），欧洲克罗恩病和结肠炎组织和牛津大学出版社。由于数据差异，撤消已被同意。共有274例患者被误分配至“ CT-P13”治疗组以进行数据分析。这些患者在入选研究之前曾接受过Remicade治疗，